Medical technology company BD has recently released the BD Rhapsody TCR/BCR Multiomic Assay, a set of reagents that enables researchers to more easily and comprehensively analyse cells, providing a tool to advance research in autoimmune disorders, immuno-oncology and infectious diseases.
The multiomic assay supplies immunology researchers the specific reagents required to profile full-length T cell and B cell receptors to better understand the adaptive immune response and enable applications such as evaluating cellular responses to new drugs.
“Understanding the contribution of these heterogeneous cell subsets at the single-cell level is of extreme relevance,” said Susan Ribeiro, PhD, Assistant Professor, Emory University School of Medicine. “This coupling of single RNAseq/AbSeq along with TCR/BCR sequencing opens a new horizon for the understanding of the contribution of T and B cell receptors to the diversity of immune responses observed in people. The new BD RhapsodyTM TCR/BCR Multiomic Assay can be very helpful to guide the discovery of new therapeutic targets.”
Puneet Sarin, Worldwide President at BD Biosciences, said: “Single-cell analysis tools like the BD RhapsodyTM TCR/BCR Multiomic Assay and BD RhapsodyTM Single-Cell Analysis System support our customers’ need for greater sensitivity and specificity studying cells of interest and drive rapid advancements in immunology, including research in therapeutic response and cell therapy.”